Research programme: antiviral therapeutics - Cocrystal Pharma

Drug Profile

Research programme: antiviral therapeutics - Cocrystal Pharma

Alternative Names: CC 2850; CC-1845; CC-2068; CC-2069; CC-31326; CC-42344; CDI-244

Latest Information Update: 06 Apr 2016

Price : $50

At a glance

  • Originator Cocrystal Discovery
  • Developer Cocrystal Pharma Inc
  • Class Small molecules
  • Mechanism of Action Endonuclease inhibitors; Enzyme modulators; Hepatitis C virus NS 5 protein inhibitors; Polymerase inhibitors; RNA replicase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C; Norovirus infections
  • Research Dengue; Ebola virus infections; Hepatitis B; Human papillomavirus infections; Influenza virus infections; Rhinovirus infections

Most Recent Events

  • 03 Apr 2017 Cocrystal plans IND enabling studies for CC 42344 in Influenza-A virus infections in 2017
  • 15 Mar 2016 Cocrystal Pharma has patent pending for NS5B programme in Brazil, Canada, Europe and India (Cocrystal Pharma, 10-K, March 2016)
  • 15 Mar 2016 Cocrystal Pharma has patent protection for NS5B, NS5B Nuc, NS3, Ebola, Norovirus, and HIV programmes in USA (Cocrystal Pharma, 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top